Title

A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation
A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Intervention/Treatment

    mazirenwan ...
  • Study Participants

    97
Functional constipation (FC) is common with 14.3% estimated prevalence in Hong Kong, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients with FC, but there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of CHM, as well as determining the optimal dosage.
Functional constipation (FC) is a common complaint in clinical practice, with the estimated prevalence 14.3% in Hong Kong, as nearly affecting 1 million Hong Kong People in different extent. It is comparable with western population, which is 15% in North America. By the definition of Rome II criteria, FC comprises a group of functional disorders, which presents as persistent difficult, infrequent or seemingly incomplete defecation.

Constipation is often perceived to be benign, easily treated condition with short-term treatment being relatively straightforward. However, the fact is the management of FC is perplexed as some subjects complain of constipation more than decade. Moreover, chronic constipation can develop into more serious bowel complaints, such as faecal impaction, incontinence and bowel perforations. There is also accumulating evidence shown that constipated subjects have significantly higher anxiety and depression scores and lower quality of life. Therefore, the demand of effective agents to normalize bowel function is extremely large.

Conventional treatment for constipation mainly relies on dietary fibre and laxatives. Although there is no credible evidence that any serious problem is associated with their prolonged use, the treatment of it has been suboptimal. First, a recent systematic review pointed out that there were paucity of trials for many commonly used agents, therefore, their use might not be well validated. Second, many patients with severe constipation do not respond adequately or lose of effectiveness after a short period of time. Third, many patients who intake dietary fibre complain of flatulence, distension, bloating and poor taste. As a result, the compliance is low as about 50%. Fourth, the use of osmotic laxatives, such as polyethylene glycol, become increasingly popular due to fewer side effects and better taste, however, the prices are much more expensive than other medications. Many constipation sufferers seek help from alternative medicine, especially from Chinese herbal medicine. For example, according to a telephone survey in Hong Kong, more than 85% of constipated subjects seek for coping strategies, such as asking for medical consultations, taking prescribed medicine and seeking for alternative therapy, involving Chinese medicine.

Traditional Chinese medicine (TCM) is particularly attractive as their effectiveness in treating functional disorders and retaining balance of body functions. The CHM used in study is derived from classic text of Chinese medicine (Shang Han Lun, Discussion of Cold-induced Disorders), which can "moisten the intestines, drain heat, promote the movement of qi and unblock the bowel".

It is well known that randomized controlled trial (RCT) is the gold standard to test the efficacy of intervention, thus in this project, we attempt to follow the basic requirements of RCT to testify the efficacy and safety of CHM on FC, as well as to determine the optimal dosage. We believe such study will benefit the advancement of CHM, or even as the foundation of research study in future.
Study Started
Oct 31
2006
Primary Completion
Aug 31
2007
Study Completion
Oct 31
2007
Results Posted
Dec 16
2011
Estimate
Last Update
Apr 24
2015
Estimate

Drug MaZiRenWan (MZRW) Low dose

Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

  • Other names: Hemp Seed Pill

Drug MaZiRenWan (MZRW) Median dose

Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

  • Other names: Hemp Seed Pill

Drug MaZiRenWan (MZRW) High dose

Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks

  • Other names: Hemp Seed Pill

MaZiRenWan (MZRW) Low dose Experimental

MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks

MaZiRenWan (MZRW) Median dose Experimental

MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks

MaZiRenWan (MZRW) High dose Experimental

MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks

Criteria

Inclusion Criteria:

Clinical diagnosis of functional constipation with Rome II criteria
General stool type belongs to Type 1 to 4 according to Bristol Stool Form Scale
Complete spontaneous bowel movement≦2 movements per week

Exclusion Criteria:

Anti-diarrhoeal therapy
Drug-induced constipation
Medical history of important bowel pathology, such as inflammatory bowel disease, congenital or acquired megacolon / megarectum
Medical history of previous abdominal surgery
Taking chronic medications that contain any kind of herbs, mineral, or specific vitamin supplements
Medical history of carbohydrate malabsorption, hormonal disorder, cancer, diabetes mellitus, hypothyroidism, asthma, renal impairment and/or any other serious diseases
History of laxative abuse
History of allergy to Chinese herbal medicine
Psychiatric or addictive disorders
Pregnancy or breast-feeding
Any other serious diseases

Summary

Low Dose Group

Median Dose Group

High Dose Group

All Events

Event Type Organ System Event Term Low Dose Group Median Dose Group High Dose Group

Responder for Complete Spontaneous Bowel Movement (CSBM)

Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders.CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

Low Dose Group

Non-responder

22.0
participants

Responder

10.0
participants

Median Dose Group

Non-responder

18.0
participants

Responder

14.0
participants

High Dose Group

Non-responder

15.0
participants

Responder

17.0
participants

Responder for Complete Spontaneous Bowel Movement (CSBM)

Participants with a mean increase of CSBM>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

Low Dose Group

Non-responder

23.0
participants

Responder

9.0
participants

Median Dose Group

Non-responder

22.0
participants

Responder

10.0
participants

High Dose Group

Non-responder

21.0
participants

Responder

11.0
participants

Bowel Movement

Low Dose Group

Wk11-18

3.9
movements per week (Mean)
Standard Deviation: 1.6

Wk1-2

3.6
movements per week (Mean)
Standard Deviation: 1.5

Wk3-10

4.2
movements per week (Mean)
Standard Deviation: 1.7

Median Dose Group

Wk11-18

3.5
movements per week (Mean)
Standard Deviation: 1.2

Wk1-2

3.1
movements per week (Mean)
Standard Deviation: 1.4

Wk3-10

4.8
movements per week (Mean)
Standard Deviation: 1.8

High Dose Group

Wk11-18

5.2
movements per week (Mean)
Standard Deviation: 4.2

Wk1-2

4.7
movements per week (Mean)
Standard Deviation: 4.1

Wk3-10

6.5
movements per week (Mean)
Standard Deviation: 5.5

Complete Spontaneous Bowel Movement (CSBM)

CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

Low Dose Group

Week11-18

1.4
movements per week (Mean)
Standard Deviation: 1.5

Week1-2

0.5
movements per week (Mean)
Standard Deviation: 0.6

Week3-10

1.4
movements per week (Mean)
Standard Deviation: 1.4

Median Dose Group

Week11-18

1.0
movements per week (Mean)
Standard Deviation: 1.2

Week1-2

0.5
movements per week (Mean)
Standard Deviation: 0.7

Week3-10

1.6
movements per week (Mean)
Standard Deviation: 1.5

High Dose Group

Week11-18

1.3
movements per week (Mean)
Standard Deviation: 1.6

Week1-2

0.5
movements per week (Mean)
Standard Deviation: 0.7

Week3-10

2.0
movements per week (Mean)
Standard Deviation: 2.1

Global Symptoms Improvement

Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.

Low Dose Group

Week10-Improved

20.0
participants

Week10-Same

10.0
participants

Week10-Worse

2.0
participants

Week18-Improved

20.0
participants

Week18-Same

11.0
participants

Week18-Worse

1.0
participants

Week6-Improved

25.0
participants

Week6-Same

4.0
participants

Week6-Worse

3.0
participants

Median Dose Group

Week10-Improved

27.0
participants

Week10-Same

5.0
participants

Week10-Worse

Week18-Improved

14.0
participants

Week18-Same

14.0
participants

Week18-Worse

4.0
participants

Week6-Improved

24.0
participants

Week6-Same

7.0
participants

Week6-Worse

1.0
participants

High Dose Group

Week10-Improved

24.0
participants

Week10-Same

6.0
participants

Week10-Worse

2.0
participants

Week18-Improved

20.0
participants

Week18-Same

12.0
participants

Week18-Worse

Week6-Improved

26.0
participants

Week6-Same

4.0
participants

Week6-Worse

2.0
participants

Severity of Constipation

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

2.62
Units on a scale (Mean)
Standard Deviation: 1.88

Week18

3.03
Units on a scale (Mean)
Standard Deviation: 1.91

Week2

4.22
Units on a scale (Mean)
Standard Deviation: 1.07

Week6

2.72
Units on a scale (Mean)
Standard Deviation: 1.87

Median Dose Group

Week10

2.06
Units on a scale (Mean)
Standard Deviation: 1.76

Week18

2.91
Units on a scale (Mean)
Standard Deviation: 1.92

Week2

4.06
Units on a scale (Mean)
Standard Deviation: 1.32

Week6

2.03
Units on a scale (Mean)
Standard Deviation: 1.84

High Dose Group

Week10

2.06
Units on a scale (Mean)
Standard Deviation: 1.81

Week18

2.38
Units on a scale (Mean)
Standard Deviation: 1.74

Week2

4.25
Units on a scale (Mean)
Standard Deviation: 1.46

Week6

2.03
Units on a scale (Mean)
Standard Deviation: 1.75

Sensation of Straining

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

2.56
Units on a scale (Mean)
Standard Deviation: 1.92

Week18

2.69
Units on a scale (Mean)
Standard Deviation: 1.86

Week2

4.03
Units on a scale (Mean)
Standard Deviation: 1.06

Week6

2.62
Units on a scale (Mean)
Standard Deviation: 1.79

Median Dose Group

Week10

2.06
Units on a scale (Mean)
Standard Deviation: 1.70

Week18

2.78
Units on a scale (Mean)
Standard Deviation: 1.88

Week2

3.53
Units on a scale (Mean)
Standard Deviation: 1.61

Week6

1.84
Units on a scale (Mean)
Standard Deviation: 1.73

High Dose Group

Week10

1.94
Units on a scale (Mean)
Standard Deviation: 1.74

Week18

2.34
Units on a scale (Mean)
Standard Deviation: 1.60

Week2

3.78
Units on a scale (Mean)
Standard Deviation: 1.60

Week6

2.16
Units on a scale (Mean)
Standard Deviation: 1.61

Incomplete of Evacuation

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

2.69
Units on a scale (Mean)
Standard Deviation: 1.91

Week18

3.0
Units on a scale (Mean)
Standard Deviation: 1.83

Week2

4.53
Units on a scale (Mean)
Standard Deviation: 1.41

Week6

2.81
Units on a scale (Mean)
Standard Deviation: 1.87

Median Dose Group

Week10

2.63
Units on a scale (Mean)
Standard Deviation: 1.64

Week18

2.94
Units on a scale (Mean)
Standard Deviation: 1.70

Week2

3.5
Units on a scale (Mean)
Standard Deviation: 1.63

Week6

2.59
Units on a scale (Mean)
Standard Deviation: 1.66

High Dose Group

Week10

2.66
Units on a scale (Mean)
Standard Deviation: 1.77

Week18

2.5
Units on a scale (Mean)
Standard Deviation: 1.67

Week2

3.97
Units on a scale (Mean)
Standard Deviation: 1.26

Week6

2.59
Units on a scale (Mean)
Standard Deviation: 1.58

Sensation of Bloating

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

1.78
Units on a scale (Mean)
Standard Deviation: 1.85

Week18

1.91
Units on a scale (Mean)
Standard Deviation: 1.69

Week2

2.53
Units on a scale (Mean)
Standard Deviation: 1.90

Week6

2.03
Units on a scale (Mean)
Standard Deviation: 1.91

Median Dose Group

Week10

1.63
Units on a scale (Mean)
Standard Deviation: 1.66

Week18

2.19
Units on a scale (Mean)
Standard Deviation: 1.86

Week2

2.75
Units on a scale (Mean)
Standard Deviation: 1.92

Week6

1.84
Units on a scale (Mean)
Standard Deviation: 1.63

High Dose Group

Week10

1.75
Units on a scale (Mean)
Standard Deviation: 1.92

Week18

1.94
Units on a scale (Mean)
Standard Deviation: 1.76

Week2

3.28
Units on a scale (Mean)
Standard Deviation: 1.87

Week6

1.91
Units on a scale (Mean)
Standard Deviation: 1.82

Sensation of Abdominal Pain/Cramping

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

0.41
Units on a scale (Mean)
Standard Deviation: 0.98

Week18

0.47
Units on a scale (Mean)
Standard Deviation: 0.92

Week2

1.0
Units on a scale (Mean)
Standard Deviation: 1.24

Week6

1.0
Units on a scale (Mean)
Standard Deviation: 1.27

Median Dose Group

Week10

1.09
Units on a scale (Mean)
Standard Deviation: 1.20

Week18

0.91
Units on a scale (Mean)
Standard Deviation: 1.25

Week2

1.12
Units on a scale (Mean)
Standard Deviation: 1.29

Week6

1.03
Units on a scale (Mean)
Standard Deviation: 1.31

High Dose Group

Week10

1.47
Units on a scale (Mean)
Standard Deviation: 1.74

Week18

0.84
Units on a scale (Mean)
Standard Deviation: 1.19

Week2

1.59
Units on a scale (Mean)
Standard Deviation: 1.68

Week6

1.5
Units on a scale (Mean)
Standard Deviation: 1.48

Passing of Gas

It was a 7-point ordinal scale from 0=not at all to 6=very severe.

Low Dose Group

Week10

1.38
Units on a scale (Mean)
Standard Deviation: 1.24

Week18

1.25
Units on a scale (Mean)
Standard Deviation: 1.19

Week2

2.37
Units on a scale (Mean)
Standard Deviation: 1.70

Week6

2.03
Units on a scale (Mean)
Standard Deviation: 1.49

Median Dose Group

Week10

2.06
Units on a scale (Mean)
Standard Deviation: 1.27

Week18

2.19
Units on a scale (Mean)
Standard Deviation: 1.36

Week2

2.59
Units on a scale (Mean)
Standard Deviation: 1.43

Week6

1.97
Units on a scale (Mean)
Standard Deviation: 1.49

High Dose Group

Week10

2.38
Units on a scale (Mean)
Standard Deviation: 1.56

Week18

2.53
Units on a scale (Mean)
Standard Deviation: 1.63

Week2

3.34
Units on a scale (Mean)
Standard Deviation: 1.29

Week6

2.44
Units on a scale (Mean)
Standard Deviation: 1.46

Adverse Effects (e.g. Renal and Liver Function Tests)

Outcome Measure Data Not Reported

Blood Urea Level

Low Dose Group

Week10

4.4
mmol/L (Mean)
Standard Deviation: 1.18

Week2

4.68
mmol/L (Mean)
Standard Deviation: 1.23

Median Dose Group

Week10

4.41
mmol/L (Mean)
Standard Deviation: 0.94

Week2

4.54
mmol/L (Mean)
Standard Deviation: 1.12

High Dose Group

Week10

4.3
mmol/L (Mean)
Standard Deviation: 1.26

Week2

4.31
mmol/L (Mean)
Standard Deviation: 1.25

Blood Creatinine Level

Low Dose Group

Week10

58.81
μmol/L (Mean)
Standard Deviation: 10.17

Week2

58.81
μmol/L (Mean)
Standard Deviation: 13.22

Median Dose Group

Week10

60.06
μmol/L (Mean)
Standard Deviation: 17.27

Week2

58.0
μmol/L (Mean)
Standard Deviation: 15.23

High Dose Group

Week10

58.09
μmol/L (Mean)
Standard Deviation: 13.74

Week2

57.38
μmol/L (Mean)
Standard Deviation: 12.46

Serum Glutamic Pyruvic Transaminase(SGPT) Level

Low Dose Group

Week10

33.44
U/L (Mean)
Standard Deviation: 8.99

Week2

32.38
U/L (Mean)
Standard Deviation: 6.95

Median Dose Group

Week10

34.06
U/L (Mean)
Standard Deviation: 6.67

Week2

32.78
U/L (Mean)
Standard Deviation: 5.33

High Dose Group

Week10

34.16
U/L (Mean)
Standard Deviation: 7.32

Week2

34.06
U/L (Mean)
Standard Deviation: 9.01

Serum Glutamic Oxaloacetic Transaminase(SGOT) Level

Low Dose Group

Week10

18.69
U/L (Mean)
Standard Deviation: 5.04

Week2

18.5
U/L (Mean)
Standard Deviation: 5.01

Median Dose Group

Week10

19.09
U/L (Mean)
Standard Deviation: 5.08

Week2

18.28
U/L (Mean)
Standard Deviation: 4.30

High Dose Group

Week10

19.09
U/L (Mean)
Standard Deviation: 5.57

Week2

19.44
U/L (Mean)
Standard Deviation: 5.29

Total

96
Participants

Age, Continuous

36.8
years (Mean)
Standard Deviation: 9.6

Bowel Movement

3.8
movements per week (Mean)
Standard Deviation: 2.7

Complete Spontaneous Bowel Movement (CSBM)

0.5
movements per week (Mean)
Standard Deviation: 0.7

Duration of constipation

13.2
years (Mean)
Standard Deviation: 9.9

No. of days taking rescue therapy

2.1
days per week (Mean)
Standard Deviation: 3.1

Severity of Constipation

4.2
Units on a scale (Mean)
Standard Deviation: 1.3

Sex: Female, Male

Overall Study

Low Dose Group

Median Dose Group

High Dose Group

Drop/Withdrawal Reasons

Low Dose Group

Median Dose Group

High Dose Group